About the network
The Lung Cancer Policy Network brings together a range of lung cancer expertise including screening, patient organisations and industry partners. Our members contribute their time for free. The Network’s activities are led by its members, with all materials representing a consensus view of the experts contributing to the Network. All outputs produced by the Network are non-promotional.
The Network is funded by multiple organisations. Details of funding tiers are included in the Terms of Reference.
Read the full Network Terms of Reference
The full Terms of Reference for the Network can be downloaded by clicking the button below. All Network members agree to the Terms of Reference, and any edits to the these are made by Network members’ consensus.
Read hereSteering Committee
The Network’s Secretariat works under the guidance of a Steering Committee. To ensure appropriate representation from each category of Network members, the Steering Committee is comprised of Major Funders, Patient organisations and representatives in addition to Scientific advisors and professional organisations.
The Steering Committee was established in 2023. Prior to this, the Network worked under the guidance of an Interim Advisory Committee.
Current members of the Network Steering Committee:
- Andrea Borondy Kitts, Rescue Lung Society
- Angela Barry, GO2 for Lung Cancer
- Catharine Grimes, Bristol Myers Squibb Foundation
- David LeDuc, AstraZeneca
- Helen Haggart, Johnson & Johnson
- Herbert Loong, The Chinese University of Hong Kong
- Jennifer King, IASLC
- Joelle Fathi, GO2 for Lung Cancer
- John Field, University of Liverpool
- Karen Kelly, International Association for the Study of Lung Cancer (IASLC)
- Maria Isabella Grueso, Pfizer
- Mariusz Adamek, Medical University of Silesia & Medical University of Gdansk
- Merel Hennink, Global Lung Cancer Coalition
- Michael Hartevelt, MSD
- Murry Wynes, IASLC
- Nadia Pellanda, MSD
- Sebastian Schmidt, Siemens Healthineers
- Victoria Schnieder, Siemens Healthineers
As well as individual members, the Network also includes member organisations that contribute to the Network:
- American College of Radiology (ACR)
- American Lung Cancer Screening Initiative (ALCSI)
- Asia Pacific Coalition Against Lung Cancer (APCLC)
- Campaigning for Cancer
- Cancer Australia
- Chinese Alliance Against Lung Cancer (CAALC)
- FairLife Lung Cancer Care
- Global Action on Men’s Health (GAMH)
- Global Lung Cancer Coalition (GLCC)
- GO2 for Lung Cancer
- International Association for the Study of Lung Cancer (IASLC)
- International Early Lung Cancer Action Program (I-ELCAP)
- Lung Cancer Consortium Singapore
- Lung Cancer Europe (LuCE)
- Lung Cancer Network Malaysia
- Lung Connect India Foundation
- LUNGevity
- Lung Foundation Australia
- Lung Health Foundation Canada
- Prevent Cancer Foundation
- Rescue Lung Society
- Roy Castle Lung Foundation
- The Israel Lung Cancer Foundation
- United Kingdom Lung Cancer Coalition (UKLCC)
- Vision Zero Cancer
- Women Against Lung Cancer in Europe (WALCE)
How the Network is funded
The Network is funded by multiple organisations. Details of funding tiers are included in the Terms of Reference.
Funders
- AstraZeneca
- Bristol Myers Squibb Foundation
- Johnson & Johnson
- MSD
- Pfizer
- Siemens Healthineers
- GE HealthCare
- Guardant Health
- Intuitive
Funders and partners
Secretariat
The Secretariat for the Network is provided by The Health Policy Partnership (HPP), an independent health policy organisation. HPP coordinates and delivers all Network activities, engages members and new Funders, and provides operational support for the Network.
